| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 2412- | TTT, | A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights |
| - | Review, | GBM, | NA |
| 6453- | TUR, | Pharmacological Profile, Bioactivities, and Safety of Turmeric Oil |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 942- | UA, | Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling |
| - | vitro+vivo, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5017- | UA, | Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells |
| - | in-vitro, | Cerv, | INT-407 | - | in-vitro, | CRC, | HCT116 |
| 4860- | Uro, | Urolithins–gut Microbial Metabolites with Potential Health Benefits |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4836- | Uro, | Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation |
| - | in-vitro, | Var, | NA |
| 4846- | Uro, | Urolithin A exerts anti-tumor effects on gastric cancer via activating autophagy-Hippo axis and modulating the gut microbiota |
| - | in-vivo, | GC, | NA |
| 4848- | Uro, | OXA, | Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells |
| - | in-vitro, | Colon, | HCT116 |
| 4849- | Uro, | Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway |
| - | vitro+vivo, | GC, | NA |
| 4852- | Uro, | Dietary Urolithin B Suppresses Lung Tumorigenesis Correlating with Autophagy Induction and Gut Microbiota Remodeling |
| - | vitro+vivo, | Lung, | NA |
| 4853- | Uro, | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
| - | vitro+vivo, | PC, | MIA PaCa-2 | - | in-vitro, | NA, | PANC1 |
| 8159- | UsA, | Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity |
| - | in-vitro, | Cerv, | HeLa |
| 1888- | VitB1/Thiamine, | DCA, | High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate |
| - | in-vitro, | PC, | SK-N-BE | - | NA, | PC, | PANC1 |
| 4328- | VitB5, | Pantethine |
| - | Review, | AD, | NA |
| 2485- | VitC, | TACE, | High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma |
| - | Case Report, | HCC, | NA |
| 3145- | VitC, | Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose‐induced oncogenic effect by downregulating the Warburg effect |
| - | in-vitro, | CRC, | HCT116 |
| 3119- | VitC, | Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma |
| - | in-vitro, | RCC, | NA |
| 3137- | VitC, | Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose-induced oncogenic effect by downregulating the Warburg effect |
| - | in-vitro, | CRC, | HCT116 |
| 617- | VitC, | Chemo, | The Use of Vitamin C with Chemotherapy in Cancer Treatment: An Annotated Bibliography |
| - | Review, | Var, | NA |
| 300- | VitC, | ALA, | Combination of High-Dose Parenteral Ascorbate (Vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect But Increased Toxicity in Preclinical Cancer Models |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Ovarian, | PANC1 | - | in-vitro, | Pca, | PC3 |
| 1840- | VitK2, | The mechanisms of vitamin K2-induced apoptosis of myeloma cells |
| - | in-vitro, | Melanoma, | NA |
| 1829- | VitK2, | Vitamin K: New insights related to senescence and cancer metastasis |
| - | Review, | Var, | NA |
| 1817- | VitK2, | Research progress on the anticancer effects of vitamin K2 |
| - | Review, | Var, | NA |
| 1818- | VitK2, | New insights on vitamin K biology with relevance to cancer |
| - | Review, | Var, | NA |
| 1835- | VitK3, | VitC, | Potential therapeutic application of the association of vitamins C and K3 in cancer treatment |
| - | Review, | Var, | NA |
| 1834- | VitK3, | PDT, | Effects of Vitamin K3 Combined with UVB on the Proliferation and Apoptosis of Cutaneous Squamous Cell Carcinoma A431 Cells |
| - | in-vitro, | Melanoma, | A431 |
| 1838- | VitK3, | PDT, | Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways |
| - | in-vitro, | Cerv, | NA |
| - | in-vitro, | Oral, | NA | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | HaCaT |
| 7914- | VT, | Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells |
| - | vitro+vivo, | Lung, | A549 |
| 7909- | VT, | Vitexin Inhibits Gastric Cancer Growth and Metastasis through HMGB1-mediated Inactivation of the PI3K/AKT/mTOR/HIF-1α Signaling Pathway |
| - | vitro+vivo, | GC, | NA |
| 1751- | WBV, | Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | AML, | RAW264.7 |
| 1755- | WBV, | Reduction of breast cancer extravasation via vibration activated osteocyte regulation |
| - | Study, | BC, | NA |
| 9144- | WN, | Walnuts Have Potential for Cancer Prevention and Treatment in Mice |
| - | Review, | Var, | NA |
| 9131- | ZYF, | Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets |
| - | vitro+vivo, | PC, | NA |
| 9132- | ZYF, | Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 9128- | ZYF, | Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression |
| - | in-vitro, | Pca, | LNCaP |
| 9124- | ZYF, | Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer |
| - | in-vitro, | Pca, | NA |
| 2425- | γ-Toc, | Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis |
| - | in-vitro, | Var, | MCF7 | - | in-vivo, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:323 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid